Reports Q2 revenue $381.3M, consensus $374.07M. “The strong organic growth of our Codman Specialty Surgical segment and several product lines in our Tissue Technologies business demonstrate the resilience of our diversified portfolio of leading brands and technologies and strong market recovery. Excluding the impact of the Boston recall, we delivered solid, mid-single digit organic growth from the underlying business,” said Jan De Witte, Integra LifeSciences’ president and CEO. “We are confident in our plans for the CereLink relaunch and the restart of our Boston manufacturing facility, and we continue to advance our implant-based breast reconstruction PMA strategy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports Second Quarter 2023 Financial Results
- Integra Lifesciences (IART) Q2 Earnings Cheat Sheet
- Integra LifeSciences price target raised to $48 from $44 at Truist
- Integra LifeSciences upgraded to Buy from Hold at Jefferies
- Integra LifeSciences to Host Second Quarter 2023 Financial Results Conference Call on July 27, 2023